Results 171 to 180 of about 131,634 (310)

Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients. [PDF]

Front Microbiol, 2022
Zhang H, Jia Y, Ji Y, Cong X, Liu Y, Yang R, Kong X, Shi Y, Zhu L, Wang Z, Wang W, Fei R, Liu F, Lu F, Chen H, Rao H.   +15 more
europepmc   +1 more source

Sphinganine‐phosphate prevents influenza infection via promoting CD8+ T cells proliferation and activation

VIEW, EarlyView.
This study established clinical cohorts of respiratory viral infections and identified sphinganine‐phosphate (SA) as a metabolite significantly upregulated post‐infection through metabolomic analysis. In vitro and in vivo experiments demonstrated that SA promotes the generation of effector CD8+ T cells via the SOCS1/JAK1/STAT1 pathway, which ...
Zhongwen Hu, Guiling Yan, Junhong Li, Yuan Yuan, Hong Zhang, Yuchao Zhong, Yuanyuan Peng, Wenjia Zhang, Xiaoyan Su, Changchun Niu, Yang Luo   +10 more
wiley   +1 more source

Identification of metabolic signatures of immune response following mRNA and inactivated vaccines against COVID-19: a systematic review. [PDF]

Front Immunol
Wasilewski A, Serrafi A.
europepmc   +1 more source

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. [PDF]

Lancet Microbe, 2021
Lim WW, Mak L, Leung GM, Cowling BJ, Peiris M.   +4 more
europepmc   +1 more source

Cholera Vaccine Inactivated Oral

Drugs in R & D, 1999
openaire   +2 more sources

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Pre-Existing Th1 Immunity Outperforms Age in Predicting Antibody Responses to SARS-CoV-2 Inactivated Vaccines. [PDF]

Adv Sci (Weinh)
Ye C, Zhang X, Qiu L, Ji J, Gu J, Jia H, Lu Y, Chen J, Meng Z, Lian J, Yao H, Zeng X, Yang Y.   +12 more
europepmc   +1 more source

Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines. [PDF]

Int J Biol Sci, 2022
Ye ZW, Fan Y, Tang K, Ong CP, Luo C, Chung HL, Leong TL, Liang R, Lui WY, Zhou R, Cheng Y, Lu L, Cheung PH, Chan JF, Chen Z, Yuen KY, Yuan S, To KK, Jin DY.   +18 more
europepmc   +1 more source

Tick‐Borne Encephalitis (TBE) Vaccine in the National Immunisation Programme—For Whom, When and Where?

Acta Paediatrica, EarlyView.
ABSTRACT The incidence of Tick‐borne encephalitis (TBE) cases has increased. The presumed location of transmission of Tick‐borne encephalitis virus (TBEV) has been expanding increasingly in the western parts of Europe during the past decade. There has also been an increased incidence of surveillance‐reported TBE cases in southern Sweden and southern ...
H. H. Askling, D. Zavadska
wiley   +1 more source

mRNA-1010 influenza vaccine elicits distinct and enhanced humoral immunity compared to adjuvanted inactivated vaccines. [PDF]

NPJ Vaccines
Kaplonek P, Vargas R, Lee JS, Bertera H, Astley E, Girard B, Oostendorp J, Henry C, Paris R, Yu WH, Alter G.   +10 more
europepmc   +1 more source